Skip to main navigation Skip to search Skip to main content

Novel polymorphisms in HLA-DOA and HLA-DOB in B-cell malignancies

  • Netherlands Cancer Institute
  • Amsterdam UMC - Vrije Universiteit Amsterdam

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

In B cells, HLA-DO controls HLA-DM-mediated peptide loading on MHC class II molecules. We analyzed whether HLA-DO mutations are associated with autoimmune diseases characterized by an autoantibody component and with a linkage to HLA-DR or HLA-DQ. These diseases include systemic lupus erythematosus, rheumatoid arthritis, celiac disease, and Graves' disease. In addition, several B-cell leukemias were screened for mutations in HLA-DO. A limited number of polymorphisms in DOA and DOB were found, most of which are non-coding changes or result in a conserved amino acid change. A novel non-conserved Arg to Cys mutation in DOA was found in a patient suffering from chronic lymphocytic leukemia. Further analysis did not reveal any effect on the function of HLA-DO. We conclude that HLA-DO variants are not critically involved in the autoimmune diseases and B-cell leukemias studied here.
Original languageEnglish
Pages (from-to)591-595
JournalImmunogenetics
Volume54
Issue number8
DOIs
Publication statusPublished - 2002
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Novel polymorphisms in HLA-DOA and HLA-DOB in B-cell malignancies'. Together they form a unique fingerprint.

Cite this